Analyst Reco. Bio-Techne Corporation

Equities

TECH

US09073M1045

Real-time Estimate Cboe BZX Other stock markets 02:52:00 2024-05-28 pm EDT			5-day change	1st Jan Change
79.27 ^USD	-1.88%		-4.03%	+2.83%

May. 22	Citigroup Downgrades Bio-Techne to Neutral From Buy, With $85 Price Target	MT
May. 16	Bio-techne Insider Sold Shares Worth $335,377, According to a Recent SEC Filing	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Citigroup Downgrades Bio-Techne to Neutral From Buy, With $85 Price Target	May. 22	MT
Bio-techne Insider Sold Shares Worth $335,377, According to a Recent SEC Filing	May. 16	MT
Argus Adjusts Price Target on Bio-Techne to $95 From $90, Keeps Buy Rating	May. 06	MT
UBS Adjusts Price Target on Bio-Techne to $90 From $80, Maintains Buy Rating	May. 02	MT
Leerink Partners Adjusts Price Target on Bio-Techne to $95 From $85	May. 02	MT
Scotiabank Adjusts Price Target on Bio-Techne to $83 From $80	May. 02	MT
RBC Capital Adjusts Price Target on Bio-Techne to $72 From $71, Sector Perform Rating Kept	May. 02	MT
Baird Adjusts Bio-Techne Price Target to $81 From $73	May. 02	MT
Deutsche Bank Adjusts Price Target on Bio-Techne to $84 From $82	May. 01	MT
RBC Capital Adjusts Price Target on Bio-Techne to $71 From $79	Apr. 29	MT
Deutsche Bank Adjusts Bio-Techne Price Target to $82 From $85	Apr. 18	MT
RBC Raises Price Target on Bio-Techne to $79 From $75, Keeps Sector Perform Rating	Apr. 08	MT
Stephens Adjusts Bio-Techne's Price Target to $87 From $70, Keeps Overweight Rating	Feb. 02	MT
Deutsche Bank Cuts Bio-Techne Price Target to $85 From $88, Maintains Buy Rating	Feb. 02	MT
RBC Cuts Price Target on Bio-Techne to $75 From $85, Notes Revenue Growth Turned Negative, Keeps Sector Perform Rating	Feb. 02	MT
Stifel Nicolaus Downgrades Bio-Techne to Hold from Buy, $65 Price Target	Feb. 02	MT
UBS Initiates Coverage on Bio-Techne With Buy Rating, $80 Price Target	Dec. 07	MT
Deutsche Bank Cuts Bio-Techne Price Target to $70 From $100, Maintains Buy Rating	Nov. 01	MT
KeyBanc Cuts Price Target on Bio-Techne to $80 From $115, Maintains Overweight Rating	Nov. 01	MT
RBC Trims Price Target on Bio-Techne to $83 From $85, Keeps Sector Perform Rating	Nov. 01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Bio-Techne Corporation

Equities

TECH

US09073M1045

Analyst Reco.

Filters